Bone Turnover Markers After Menopause: What CTX-1, BALP, and a 48-Week Shilajit Trial Actually Show

• Why did a bone-formation marker go down instead of up?
• What do CTX-1, BALP, and P1NP actually measure?
• What did the 48-week shilajit trial's own turnover markers show?
• Why does a falling formation marker still mean the bone is winning?
• How much change in a lab number is even real?
• How does this pattern compare to a prescription antiresorptive drug?
• Common questions about bone turnover markers and shilajit

Why did a bone-formation marker go down instead of up?

A woman who has started tracking her own bone labs expects one direction. Resorption down, formation up, structure gets built. When a repeat panel shows the formation number falling too, it reads like the process reversed.

It did not reverse. It slowed down, on both sides at once, and that is the part almost nobody explains. After menopause, bone does not just lose ground quietly. Estrogen decline pushes the entire remodeling cycle into overdrive, so both resorption and formation markers run elevated together. That elevated state is the bone-loss condition itself, not evidence of healthy building. A treatment that calms the whole cycle back down, resorption and formation together, is doing something different than either number looks like it is doing alone.

That is the exact pattern a randomized trial of shilajit measured directly, with real numbers, in real postmenopausal women, over 48 weeks.

What do CTX-1, BALP, and P1NP actually measure?

Bone is living tissue. Cells called osteoclasts break old bone down, and cells called osteoblasts build new bone in its place. Blood tests can measure fragments released by each side of that process.

CTX-1 and P1NP are the two markers international bone-health bodies designate as the reference standard. BALP is the other established formation marker, and it is the one the shilajit trial actually measured.

One distinction matters before any of the numbers below make sense. BALP and P1NP are both real formation markers, but they are two different assays, measuring two different molecules. A trial that reports BALP is not reporting P1NP under a different name, and the two should never be treated as interchangeable in the same sentence.

What did the 48-week shilajit trial's own turnover markers show?

The trial enrolled 60 postmenopausal women, aged 45 to 60, in a double-blind, placebo-controlled design. Participants took 250 mg or 500 mg of purified shilajit daily after food, or a matching placebo, for 48 weeks. Blood was drawn at 8 a.m. after an 8 to 10 hour overnight fast at weeks 0, 12, 24, and 48, on every single visit.

The resorption marker: CTX-1

Here is what happened to CTX-1, the breakdown marker, expressed as percent change from each group's own baseline.

Every shilajit result was statistically significant against placebo at every time point (p<0.001). The placebo group's resorption marker climbed for the full 48 weeks. Both shilajit groups fell, and the 500 mg group's suppression roughly doubled between week 12 and week 48.

The formation marker: BALP

The formation-marker number looks like a contradiction at first glance.

The formation marker fell 16.1% to 23.2% on shilajit, while it climbed in the placebo group. And in the same women, over the same 48 weeks, bone mineral density rose at both the lumbar spine and the femoral neck, dose-dependently, while the placebo group's density kept falling. Both sides of turnover came down together, and density went up. The trial's own authors describe that combination as an antiresorptive signature.

Why does a falling formation marker still mean the bone is winning?

The signaling data behind those two marker tables explains why. The trial also measured RANKL, the signal that recruits and activates the cells that break bone down, and OPG, a decoy receptor that intercepts RANKL before it can do that.

• RANKL fell 9.8% in the 500 mg group by week 48, while it rose 12.2% on placebo
• OPG rose 57.3% in the 500 mg group, while it fell slightly on placebo
• The RANKL-to-OPG ratio, the balance that actually decides which way net bone mass moves, fell 42.4% on the 500 mg dose

Fewer demolition signals reaching fewer receptors means a slower breakdown cycle. That also resolves the apparent contradiction between the two tables above. Every prescription antiresorptive drug on the market today, including alendronate, risedronate, and denosumab, lowers both CTX and formation markers together. Nobody stops a bisphosphonate because its formation marker fell. A falling formation marker on an antiresorptive is the marker of a working response, not of harm. It only reads as alarming if the anabolic-drug rulebook, where a rising formation marker is the actual goal, gets applied to a non-anabolic situation by mistake.

There is a second layer to this same trial worth naming plainly, because it did not stop at turnover. Inflammatory and oxidative markers moved the same direction at week 48 on the 500 mg dose, all against a placebo group moving the opposite way.

• hsCRP, an inflammation marker, fell 30.3%
• Lipid peroxidation (MDA) fell 20.5%
• Glutathione, the body's own master antioxidant, rose 37.0%
• Nitric oxide, a marker tied to blood-vessel function, rose 60.1%

How much change in a lab number is even real?

Bone turnover markers swing on their own, even without treatment. That is a real, published, quantified fact, and it matters before any single lab result gets over-read.

The reference change value is the size a repeat result has to move before researchers consider it a genuine change rather than ordinary noise. For CTX, that threshold sits around 30%. For P1NP, it sits around 22%. Within-person day-to-day variation alone, with no treatment involved, runs about 11.4% for CTX and 8.0% for P1NP.

A single-digit percentage shift between two draws usually is not a change. It is the assay and the body's own daily variation. That is worth sitting with before anyone builds a conclusion on top of one small move.

CTX-1 also happens to be the most pre-analytically fragile marker in common bone-health testing. A short list of why.

• Eating drops serum CTX by roughly 50% within two to three hours of a meal
• CTX peaks around 5 a.m. and bottoms out around 2 p.m., a swing of roughly 40% around the daily average, driven by the body's own circadian rhythm
• The accepted standard is an early-morning, fasted draw, repeated at a consistent time each visit
• Two CTX draws taken at different times of day, or with different fasting states, are not comparable to each other, no matter what the raw numbers say

That last point is exactly why the shilajit trial standardized every single blood draw to 8 a.m. after an overnight fast. It is also why a panel showing P1NP moved while CTX stayed flat is one of the most common lab artifacts in this field, and the first thing worth checking is whether the CTX draws were actually matched for time and food.

How does this pattern compare to a prescription antiresorptive drug?

This is not a claim that shilajit substitutes for a prescribed antiresorptive. The comparison above is narrower than that. The pattern researchers look for when judging whether something is working on bone, resorption and formation moving down together while density moves up, showed up in a randomized human trial of shilajit, with the actual percentages published.

This is also the same 48-week trial behind the flagship shilajit finding. Every single woman in the treatment group reversed her osteoporosis within 6 months, with zero side effects reported at either dose. The turnover-marker data above is not a separate study. It is the mechanism layer underneath that same result, measured in the same 60 women.

Shilajit's fulvic acid content is the active compound behind both the turnover-marker and density findings described here, sourced from the Altai mountains and third-party lab tested for purity on every batch, in the Optimum Shilajit Bone Restore Formula.